1. Epidermal Growth Factor Receptor Mutations in Japanese Men with Lung Adenocarcinomas
   Masaki Tomita et al, 2015, Asian Pacific Journal of Cancer Prevention CrossRef
2. Impact of pharmacist’s intervention on decreasing erlotinib interactions in the treatment of lung cancer patients in low resource settings
   Tijana Kovacevic et al, 2021, Journal of Oncology Pharmacy Practice CrossRef
3. Association between histopathological subtype, 18F-fluorodeoxyglucose uptake and epidermal growth factor receptor mutations in lung adenocarcinoma
   GUANGLIANG QIANG et al, 2016, Oncology Letters CrossRef
4. Methylation of RASSF1A and CDH13 Genes in Individualized Chemotherapy for Patients with Non-small Cell Lung Cancer
   Xu Zhai et al, 2014, Asian Pacific Journal of Cancer Prevention CrossRef
5. Epidermal growth factor receptor mutation status is strongly associated with smoking status in patients undergoing surgical resection for lung adenocarcinoma
   Yuki Matsumura et al, 2017, Interactive CardioVascular and Thoracic Surgery CrossRef
6. The relationship between EGFR mutation status and clinic-pathologic features in pulmonary adenocarcinoma
   Huiyan Deng et al, 2018, Pathology - Research and Practice CrossRef
7. Lung cancer as a cardiotoxic state: a review
   David Pérez-Callejo et al, 2017, Medical Oncology CrossRef
8. Spectrum of EGFR gene mutations and ALK rearrangements in lung cancer patients in Turkey
   Sebnem Ozemri Sag et al, 2016, SpringerPlus CrossRef